Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-Label Dose Escalation and Expansion Study of SNV1521 in Participants With Advanced Solid Tumors

NCT06220864 is registered in ClinicalTrials.gov with Synnovation Therapeutics, Inc. as lead sponsor.

NCT NCT06220864
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06220864 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-Label Dose Escalation and Expansion Study of SNV1521 in Participants With Advanced Solid Tumors
Lead sponsor
Synnovation Therapeutics, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
February 23, 2024
Completion date
December 31, 2027
Enrollment
400 (estimated)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor